



MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

September 28, 2021

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am (ET). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.

Interested parties can access a link to the live webcast of the presentations from the Events & Presentations section of the Company's website at <https://investors.mannkindcorp.com/events-and-presentations>. The webcast replay may be accessed at the same location for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza[®] (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:

Rose Alinaya, Investor Relations

(818) 661-5000

Email: ir@mannkindcorp.com



Source: MannKind